1-甲基-4-(2-[(4-甲基苯基)磺酰基]乙基)哌嗪 | 16191-68-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-甲基-4-(2-[(4-甲基苯基)磺酰基]乙基)哌嗪
• 中文别名: 1-甲基-4-(2-[(4-甲基苯基)磺酰]乙基)哌嗪
• 英文名称: 4-Methylphenyl-2-(4-methyl-1-piperazinyl)-ethyl-sulfon
• 英文别名: N-<2-(4-Methyl-phenylsulfonyl)-ethyl>-N'-methyl-piperazin；1-methyl-4-[2-(toluene-4-sulfonyl)-ethyl]-piperazine；Piperazine, 1-methyl-4-[2-(p-tolylsulfonyl)ethyl]-；1-methyl-4-[2-(4-methylphenyl)sulfonylethyl]piperazine
• CAS: 16191-68-7
• 化学式: C₁₄H₂₂N₂O₂S
• mdl: MFCD00430837
• 分子量: 282.407
• InChiKey: MMXGWBCIPHBJHP-UHFFFAOYSA-N

物化性质

• 沸点：
  450.9±45.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  49
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

文献信息

• CHIRAL CONTROL
  申请人：WAVE LIFE SCIENCES PTE. LTD.

  公开号：US20150211006A1

  公开（公告）日：2015-07-30

  The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

  本发明涉及手性控制的寡核苷酸、手性控制的寡核苷酸组合物以及其制备和使用方法。本发明特别涵盖了鉴定以前制备手性寡核苷酸方法中某些问题的来源，包括禁止制备完全手性控制的组合物，特别是包含多种寡核苷酸类型的组合物。在某些实施例中，本发明提供了手性控制的寡核苷酸组合物。在某些实施例中，本发明提供了制备手性控制的寡核苷酸和手性控制的寡核苷酸组合物的方法。
• CHIRAL DESIGN
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US20170037399A1

  公开（公告）日：2017-02-09

  The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.
• [EN] CHIRAL CONTROL<br/>[FR] CONTRÔLE CHIRAL
  申请人：ONTORII INC

  公开号：WO2014012081A2

  公开（公告）日：2014-01-16

  The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same.
• [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS D'OLIGONUCLÉOTIDES ET PROCÉDÉS ASSOCIÉS
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2017192664A1

  公开（公告）日：2017-11-09

  Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.